Search Results
Your search for The ASCO Post matches 17393 pages
Showing 9751 - 9800EXPERT POINT OF VIEW: Wafik S. El-Deiry, MD, PhD, FACP
WAFIK S. EL-DEIRY, MD, PhD, FACP, Deputy Cancer Center Director for Translational Research, and Co-Leader of the Molecular Therapeutics Program at Fox Chase Cancer Center, Philadelphia, shared his thoughts on these findings with The ASCO Post. In essence, Dr. El-Deiry suggested the comparison does ...
Investigational Genomic Tool Identifies Consensus Molecular Subtype of Colon Tumor and May Predict Risk of Recurrence
AN INVESTIGATIONAL TOOL called ColotypeR classifies colon cancers by molecular subtype and creates a subtype-specific risk of recurrence, according to research. Developers of the tool say it will be able to guide treatment decisions. Colon cancer is highly heterogeneous in prognosis and response to ...
Responses Reported With CAR T-Cell Therapy in High-Risk NHL
LISOCABTAGENE MARALEUCEL (Liso-cel; JCAR017), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy with defined composition, has shown “potent and durable” responses in poor-prognosis patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) in a phase I trial.1 According ...
Advancing Cancer Research in Challenging Times
ON OCTOBER 17, 2017, Norman E. Sharpless, MD, became the 15th Director of the National Cancer Institute (NCI), succeeding Harold E. Varmus, MD, who stepped down as Director of the agency in March 2015, and replacing Douglas R. Lowy, MD, who had served as Acting Director for 2 years. The...
Multimodal Treatment in Patients With Gleason Score 9–10 Prostate Cancer
University of California, Los Angeles (UCLA) researchers have discovered that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer. The findings, published by Kishan et al in JAMA, also...
FDA Approves sBLA Updating Nivolumab Dosing Schedule Across Indications
On March 6, Bristol-Myers Squibb announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the nivolumab (Opdivo) dosing schedule to include 480 mg infused every 4 weeks for a majority of approved indications. This approval will ...
FDA Authorizes Direct-to-Consumer Test That Reports Three Mutations in the BRCA1/BRCA2 Breast Cancer Genes
Today, the U.S. Food and Drug Administration (FDA) authorized the Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants). It is the first direct-to-consumer (DTC) test to report on three specific BRCA1/BRCA2 breast cancer gene mutations that are most common in...
Multitargeted Tyrosine Kinase Inhibitor Shows Activity in Small Cell Carcinoma of the Ovary
An multitargeted tyrosine kinase inhibitor used to treat leukemia has shown promise against a rare and aggressive type of ovarian cancer—small cell carcinoma of the ovary hypercalcemic type (SCCOHT)—that strikes young women and girls, according to a study led by the Translational...
E. John Wherry, PhD, Awarded SU2C Funding to Lead Investigation of Gynecologic Cancer Therapies
E. John Wherry, PhD, a cancer and immunology researcher at the Perelman School of Medicine at the University of Pennsylvania and one of the most highly cited investigators in his field, has been awarded a “Convergence 2.0” research grant by Stand Up to Cancer (SU2C) to investigate immune system...
Cognitive Decline Prevalent Among Elderly Patients With Hematologic Cancers
A sizable percentage of elderly patients with blood-related cancers such as leukemia and multiple myeloma are apt to show signs of diminished cognitive functioning—a decline that may impact their survival—a new study by investigators at Dana-Farber Cancer Institute and Brigham and...
Alex Huang, MD, PhD, Receives $450,000 From Pediatric Cancer Research Foundation
Cancer researcher Alex Huang MD, PhD, has received a $450,000 Basic Science grant from the Pediatric Cancer Research Foundation to study targeted approaches for effectively eliminating metastatic osteosarcoma. Dr. Huang is Professor of Pediatrics at Case Western Reserve University School of...
The Skin Cancer Foundation Announces Office Relocation
The Skin Cancer Foundation, the leading nonprofit organization for public and professional skin cancer education, recently moved to a new office space at 205 Lexington Avenue in midtown Manhattan. The new office will allow the Foundation to grow its staff as it develops new patient support programs ...
Why Right-to-Try Laws Are Dangerous
Why wouldn’t you support a patient with a terminal illness the “right to try” any therapy that may save his or her life? The answer to this question—one engulfed in a political debate in Congress—seems simple. It is not. [Editor’s Note: On May 30, 2018, the President signed into law the Trickett...
Genomic Analyses Highlight Need for Precision Therapies That Target Pediatric Cancers
Researchers have determined that children and adults with cancer often have different mutated genes driving their disease, which suggests they would likely benefit from different therapies. The finding, from a collaborative study led by St. Jude Children’s Research Hospital and published by...
FDA Grants Fast Track Designation to Pamrevlumab in Locally Advanced Unresectable Pancreatic Cancer
On March 1, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for the anti–connective tissue growth factor (CTGF) antibody pamrevlumab for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the phase II clinical...
Nut Consumption in Patients With Stage III Colon Cancer
People with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don’t, according to findings published by Fadelu et al in the Journal of Clinical Oncology. Findings The study followed 826 participants in the CALGB...
GC4419 Receives FDA Breakthrough Therapy Designation for the Reduction of Severe Oral Mucositis
On February 28, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to GC4419, a highly selective and potent small molecule dismutase mimetic, for the reduction of the duration, incidence, and severity of severe oral mucositis induced by radiation therapy with...
FDA Accepts BLA for Calaspargase Pegol in Acute Lymphoblastic Leukemia
On February 28, Shire announced that the U.S. Food and Drug Administration (FDA) accepted the company’s biologics license application (BLA) for calaspargase pegol (Cal-PEG; SHP663). The investigational-stage compound is being reviewed as a component of a multiagent chemotherapeutic regimen...
New NCCN Guidelines Aim to Encourage More People Living With HIV and Cancer to Receive Appropriate Cancer Treatment
The National Comprehensive Cancer Network® (NCCN) has released new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) intended to help make sure people living with human immunodeficiency virus (HIV) who are diagnosed with cancer receive safe, necessary treatment. According to ...
Experiences With Radiation Therapy Better Than Expected for Most Patients With Breast Cancer
A new study reveals that many patients with breast cancer have misconceptions and fears about radiation therapy, but their actual experiences with this treatment modality are better than they expected. In the study published by Shaverdian et al in Cancer, most patients agreed that their initial...
FDA Approves Abemaciclib as Initial Therapy for Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
On February 26, the U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative advanced...
FDA Grants Orphan Drug Designation to YS-ON-001 for the Treatment of Pancreatic Cancer
On February 26, Yisheng Biopharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to its lead immuno-oncology candidate, YS-ON-001, for the treatment of pancreatic cancer. YS-ON-001 is a clinical-stage immuno-oncology biologic product...
Study Shows Need for Early Supportive Care in Patients Diagnosed With Uveal Melanoma
In a study published by Williamson et al in JAMA Ophthalmology, University of California, Los Angeles, (UCLA) researchers found that nearly all patients diagnosed with uveal melanoma had a number of unmet psychological and health information needs, particularly during the first 3 months after their ...
Five Novel Genetic Changes Linked to Pancreatic Cancer Risk
In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center, the National Cancer Institute, and collaborators from over 80 other institutions worldwide discovered changes to 5 new regions in the human genome...
New Edition of Hematology: Basic Principles and Practice Now Available
THE 7th AND LATEST EDITION of Hematology: Basic Principles and Practice has been published by Elsevier. This authoritative reference in the field of hematology delivers expert scientific content and clinical guidance to enhance problem-solving skills and make optimal use of the newest diagnostic...
USPSTF Recommends Against Screening for Ovarian Cancer in Asymptomatic Women
THE U.S. PREVENTIVE Services Task Force (USPSTF) recently published a final recommendation statement and evidence summary on screening for ovarian cancer. Based on its review of the evidence, the USPSTF recommends against screening for ovarian cancer in women who do not have any signs or symptoms...
U.S. Incidence and Projected Rise of Merkel Cell Carcinoma
The number of U.S. cases of Merkel cell carcinoma is rising about six times faster than most other cancers, and at nearly twice the rate of melanoma. Paulson et al reported these findings in The Journal of the American Academy of Dermatology, which are based on research conducted at the University...
FDA Accepts NDA, Grants Priority Review for Ivosidenib in Relapsed or Refractory IDH1-Mutated AML
On February 15, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for ivosidenib (AG-120) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation. The NDA was granted Priority Review...
UCLA Scientists Receive NIH Research Grant to Advance Adoption of Focal Laser Therapy for Prostate Cancer
UNIVERSITY OF CALIFORNIA (UCLA) researchers Leonard Marks, MD, and Shyam Natarajan, PhD, will lead a $3.1 million research project grant awarded by the National Institutes of Health to advance the adoption of a promising new technology to treat men with prostate cancer. By helping to increase the ...
Priyanka Sharma, MD, Appointed Vice Chair of SWOG Breast Committee
PRIYANKA SHARMA, MD, a breast cancer medical oncologist at The University of Kansas Cancer Center, has been named Vice Chair of SWOG’s Breast Committee. SWOG, formerly the Southwest Oncology Group, is a global cancer research community that designs and conducts publicly funded clinical trials. It ...
New Head of GI Medical Oncology at Perlmutter Cancer Center
PAUL E. OBSERSTEIN, MD, will join New York University (NYU) Langone Health and its Perlmutter Cancer Center as Director of Gastrointestinal Medical Oncology and Assistant Director of the institution’s recently established Pancreatic Cancer Center. Prior to his new post at NYU Langone, Dr....
Human Genome Project Receives Thai Annual Award
THE HUMAN GENOME PROJECT has been awarded the 2017 Prince Mahidol Award, a Thai Royal Family annual award for groundbreaking advances in the fields of medicine and public health. The award was received on behalf of the project by Eric Green, MD, PhD, Director of the National Human Genome Research...
Madhav V. Dhodapkar, MBBS, Named Director of New Center for Cancer Immunology at Winship Cancer Institute
MADHAV V. DHODAPKAR, MBBS, a world-renowned expert in cancer immunology and translational immunotherapy, joined Winship Cancer Institute of Emory University as Director of the new Winship Center for Cancer Immunology. He has been appointed as the Anise McDaniel Brock Chair, Georgia Research...
FDA Approves Abiraterone Acetate Plus Prednisone for High‑Risk Metastatic Castration-Sensitive Prostate Cancer
ON FEBRUARY 7, 2018, the U.S. Food and Drug Administration (FDA) approved abiraterone acetate (Zytiga) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer. The FDA initially approved abiraterone acetate with prednisone in 2011 for patients with...
Why Palliative Care Isn’t Just for Older Patients With Cancer
It is well established that adolescents and young adults (AYAs) with cancer—defined by the National Cancer Institute as those between the ages of 15 and 39 years—have not reaped a comparable survival benefit as either younger or older adult cancer survivors over the past 4 decades, despite...
Results From Phase III ARROW Study of Once-Weekly Carfilzomib in Relapsed or Refractory Multiple Myeloma
TOPLINE RESULTS of the phase III ARROW trial (ClinicalTrials.gov identifier NCT02412878) were recently announced by Amgen. The study showed carfilzomib (Kyprolis) administered once weekly at 70 mg/m2 with dexamethasone allowed patients with relapsed or refractory multiple myeloma to live 3.6 months ...
Retrospective Analysis Suggests Obesity Associated With Longer Survival for Men With Metastatic Melanoma
OBESE PATIENTS with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal body mass index (BMI), according to a study published in The Lancet Oncology of 1,918 patients in 6 independent clinical cohorts.1 This effect—referred to as ...
ASCO Clinical Practice Guideline Update: Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
AS REPORTED in the Journal of Clinical Oncology by Arlene A. Forastiere, MD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and colleagues, ASCO has issued a clinical practice guideline update on the use of larynx-preservation strategies in the treatment of laryngeal cancer.1...
Does Treatment With Tumor-Treating Fields Plus Temozolomide Influence Quality of Life in Patients With Newly Diagnosed Glioblastoma?
A DETAILED quality-of-life analysis of the phase III EF-14 trial of tumor-treating fields (Optune) in combination with temozolomide for the treatment of newly diagnosed glioblastoma was published by Taphoorn et al in JAMA Oncology.1 This secondary endpoint analysis showed the addition of...
CancerCare Raises Nearly $665,000 to Support Patients With Cancer Affected by Hurricanes
SINCE SEPTEMBER 2017, the national nonprofit organization CancerCare has raised nearly $665,000 to provide direct financial assistance for people with cancer who have been impacted by hurricanes. The majority of this support has been allocated to people with cancer in Puerto Rico, many of whom are...
World Cancer Day Addresses Global Disparities in Cancer Care
FEBRUARY 4 was World Cancer Day, which raises awareness for the millions of people worldwide facing unequal access to cancer detection, treatment, and care services. Oncology leaders, health-care professionals, and supporters across the world are pushing for urgent action to reduce the rate of...
Combining Ultrasound Imaging With Alpha-Fetoprotein Test May Boost Detection of Hepatocellular Carcinoma
Combining ultrasound imaging with a blood test for high alpha fetoprotein levels may improve detection of early-stage liver cancer by as much as 40%, researchers at UT Southwestern’s Simmons Cancer Center found. Their findings were presented by Tzartzeva et al in Gastroenterology....
Family History Increases Breast Cancer Risk, Even in Women Aged 65 and Older
A family history of breast cancer continues to significantly increase chances of developing invasive breast tumors in women aged 65 years and older, according to research published by Braithwaite et al in JAMA Internal Medicine. The findings could impact mammography screening decisions later in...
David Baraghoshi, on Colorectal Cancer and Cardiovascular Disease Risk
David Baraghoshi, of the Huntsman Cancer Institute at the University of Utah, discusses an assessment of cardiovascular risk more than 10 years after diagnosis for colorectal cancer survivors compared with a cancer-free general population cohort (Abstract 113).
Flora E. van Leeuwen, PhD, on Hodgkin Lymphoma Treatment: Toxicities in Female Survivors
Flora E. van Leeuwen, PhD, of the Netherlands Cancer Institute, discusses cardiovascular disease risk after treatment-induced primary ovarian insufficiency in female survivors of Hodgkin lymphoma (Abstract 114).
Lawrence N. Shulman, MD, on The New Survivorship Standard: Expert Perspective
Lawrence N. Shulman, MD, of Abramson Cancer Center at the University of Pennsylvania, discusses the Commission on Cancer’s efforts to promote robust survivorship care and how its new recommendations will affect clinical practice and patients.
Christopher J. Recklitis, PhD, MPH, on Sexual Aids and Supportive Care: Study Findings
Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute, discusses a study investigating the availability of supportive care sexual aids and resources for cancer survivors at U.S. cancer centers (Abstract 134).
Christopher J. Recklitis, PhD, MPH, on Mental Health in Cancer Survivors
Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute, summarizes two key papers on mental health: suicide risk among survivors of head and neck cancer vs other types of cancer; and the fear of cancer recurrence—its associations with mental health status and individual characteristics ...
Electra D. Paskett, PhD, on Breast Cancer and Arm Mobility: Clinical Trial Results
Electra D. Paskett, PhD, of The Ohio State University Comprehensive Cancer Center, discusses study findings on whether exercise helps women with breast cancer regain arm mobility after lymph node surgery (Abstract 123).
Paul B. Jacobsen, PhD, on The Impact of Survivorship Care Plans: Expert Perspective
Paul B. Jacobsen, PhD, of the National Cancer Institute, discusses his evaluation of whether survivorship care plans have a positive impact on health outcomes and health-care delivery for cancer survivors, in both the long and short term (Abstract 2).
